HNRNPL and lung cancer: Ngoc T. Vu et al.'s study found that AKTi-1/2 can control the variable splicing of Caspase9 by inhibiting the phosphorylation of HNRNP L and promoting the up-regulation of the expression of Caspase9a subtype, thus promoting the apoptosis of lung cancer cells [119].